ardiac cell therapy represents a major new frontier in heart disease treatment, [1] [2] [3] but the basic biological mechanisms underlying the reported beneficial effects remain poorly-characterized. 4 -6 Cardiac and vascular differentiation of transplanted cells is only one of multiple pathways playing a role in the positive outcome of stem cell transplantation. An alternative explanation is the so called "paracrine hypothesis," which states that the release of cytokines and growth factors (GFs) by transplanted cells has a positive "bystander" effect on viability and recovery of the ischemic host tissue. [7] [8] [9] [10] [11] In fact, many benefits of cardiac cell therapy could be related, at least in part, to the ability of transplanted cells to secrete signaling molecules, which may influence cardiomyocyte survival, neoangiogenesis and/or possibly the recruitment of endogenous cardiac stem cells. 12 The cardiac progenitor cell population used in the present study is isolated from explant cultures of adult human endomyocardial biopsies using an intermediate cardiosphere (CSp) step. 13, 14 CSps are self-assembling spherical clusters that grow in semisuspension culture on poly-D-lysine, and that constitute a niche-like environment: undifferentiated cells proliferate in the core, whereas cardiac-committed cells grow on the periphery in a gradient fashion. CSp-derived cells (CDCs) can be expanded many fold as monolayers on fibronectin, achieving cell numbers suitable for cell therapy. CDCs have been shown 14 to improve left ventricular ejection fraction (LVEF) in SCID beige mice 3 weeks after acute myocardial infarction (MI), when compared to mice injected with vehicle or with adult normal human dermal fibroblasts (NHDFs). The clonogenicity and multilineage potential of CDCs have recently been confirmed, along with demonstration that the cells reflect neither cardiomyocyte remnants nor blood-borne contaminants. 15 Our previous work on CDCs, and that of others, 16, 17 supports the notion that such cells can directly regenerate myocardium and blood vessels. 14 In the present study, we investigated the hypothesis that paracrine mechanisms may also contribute to the beneficial effects of human CDCs. In vitro screening of conditioned media (CM) focused our study on three GFs, vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and insulin-like growth factor (IGF)-1, that have been shown to play important roles after MI, 18 -24 including reducing cell death, improving microcirculation and partially preventing remodeling. The relevance of these factors has been recently investigated in multiple cardiac cell therapy settings. 7, 9, [25] [26] [27] [28] [29] [30] We assessed whether CSps and CDCs release these GFs in vitro and whether they mediate the favorable biological effects of CDCconditioned media (CDC-CM) on neonatal rat ventricular myocytes (NRVMs) and human umbilical vein endothelial cells (HUVECs). We also investigated the release of GFs in vivo by CDCs in infarcted SCID mice, and parameters such as the expression of survival markers, apoptotic rate and capillary density in heart tissue at different time points. Finally we quantified the relative magnitudes of direct CDC differentiation and indirect paracrine effects. Our results support the notion that paracrine/humoral mechanisms play a major role in the overall beneficial effect of CDC treatment in the MI setting. This is the first report of quantification of direct and paracrine effects exerted by a cardiac resident progenitor population on cardiac tissue preservation and angiogenesis.
Methods

Cell Culture and Conditioned Media Collection
Human CSps and CDCs were obtained, as previously described, 14 from percutaneous septal endomyocardial biopsies from 21 different patients (Figure 1a ), during clinically indicated procedures after informed consent, in an institutional review board-approved protocol.
Media were conditioned for 48 hours, and were either 2.5% FBS complete explant medium (CEM), or glucose-free FBS-free basal medium (BM). See the expanded Methods section (Online Data Supplement, available at http://circres.ahajournals.org) for detailed media recipes, as well as for protocols on protein array, ELISA, luciferase-lentivirus creation and transduction.
NRVM Culture and FACS Analysis
NRVMs were isolated as described. 31 Plates were incubated in humidified 2% O 2 atmosphere for 24 or 72 hours with CM or FBS-free BM (Figure 1b ). Cells were then collected by trypsinization, labeled with Annexin V-FITC and 7AAD (BD Biosciences), and analyzed with a FACScan flow cytometer and CellQuest software (BD Biosciences).
Angiogenesis Assay
HUVECs were plated on precast, matrix-coated 96-well plates (BD Biosciences). They were plated either with endothelial cell media (Lonza), as positive control, or with CM (Figure 1b) FBS-free BM, as the negative control. Cells were imaged after 18 hours to reconstruct the complete image of every well (Online Figure I) . The total tube length was then measured with the ImageJ plug-in, NeuronJ (NIH) (http://rsb.info.nih.gov/ij).
Mouse Myocardial Infarction Model
SCID beige mice (10 weeks old) were subjected to LAD ligation as previously described, 14 and 1ϫ10 5 CDCs or NHDFs were acutely injected into the infarct border zone. Regional tissue samples were taken from infarct, border zone (BZ), right ventricle, and septum areas for Western blot (WB) and RT-PCR analysis (Figure 1b) . For sectioning, hearts were arrested in diastole, fixed in formalin and paraffin embedded. At least 3 animals per group were considered for each experimental setting. See the expanded Methods section (Online Data Supplement) for details regarding tissue sectioning, immunofluorescence, protein and RNA extraction, WB, and PCR.
LVEF was calculated with VisualSonics version 1.3.8 software from 2D long-axis views taken through the infarcted area. Optical imaging was performed in the IVIS SPECTRUM (Xenogen) imaging chamber. See the expanded Methods section (Online Data Supplement) for more details.
Statistical Analysis
All results are presented as mean valueϮstandard deviation, unless specified. Significance of difference between any two groups was determined by two-sided Student t test. A final value of PϽ0.05 was considered significant.
Results
Preliminary Protein Array Screening
Serum-free CMs from CSps and CDCs were screened for secreted factors using a protein array. We sought to identify factors that were present in both cell products but enhanced in CSps, which have properties reminiscent of stem cell niches and potent regenerative bioactivity. 13, 15 All 79 spots corresponding to various cytokines and growth factors gave a positive signal, despite variability in signal intensities. Figure 2 shows two representative blots from CSps and CDCs derived from the same patient sample, together with the corresponding densitogram, showing the CSp/CDC optical density ratios for each factor. Among the factors which showed several-fold enhancement in CSp-CM, we selected 3 candidates for further analysis, VEGF, HGF, and IGF1, based on the following criteria: (1) identity as nonimmunomodulatory factors; (2) high CSp/CDC ratio, reporting the ability to enhance secretion in 3D culture; and (3) well-known roles in cardiac pathophysiology, in particular in MI and heart failure. 7-9,18 -30 
CSps, CDCs, and Secondary Cardiospheres Release GFs In Vitro
One goal was to compare the paracrine potencies of three potential cell delivery products: CSps, CDCs, and secondary CSps that were rederived from passaged CDCs (IICSps). Analysis of low-serum CM revealed that CSps, CDCs and IICSps secrete significant amounts of GFs in culture ( Figure  3a ). During 48 hours of conditioning in low serum, CSps released VEGF, HGF, and IGF1. By contrast, in the same culture conditions, CDCs and IICSps released only VEGF in measurable amounts, although secretion by IICSps was at the level measured in CSps. Different culture settings were examined (different serum concentrations and multiple cell densities), but IGF1 secretion was never detected again after the CSp stage (data not shown). Nevertheless, CDCs can release HGF in vitro under certain conditions, as detected by ELISA in BM (Figure 3b ). Immunofluorescent analysis of CSps revealed ample VEGF, HGF, and IGF1 (Figure 3c and 3d). Reverse transcription PCR on RNA isolated from CSps, CDCs and IICSps confirmed the expression of VEGF, HGF, and IGF1 mRNAs at all stages ( Figure 3e ). No GFs were detected by ELISA in NHDF-CM in any of the conditions tested, although we could detect the expression of the corresponding mRNAs by PCR. NHDFs were also grown as spheres on poly-D-lysine, but we could detect neither cellassociated GFs by immunofluorescence (data not shown) nor secreted GFs in CM by ELISA (Figure 3a ).
CSps and CDCs also express the receptors for VEGF, HGF, and IGF1 (respectively KDR, Met, IGF1-R), as assessed by immunofluorescence and RT-PCR (Online Figure II) .
Effect of CDC-CM on NRVM Viability
CDC-and NHDF-CM were collected in FBS-free BM and used to replace NRVM media. After 24 or 72 hours in 2% hypoxia, the percentage of early apoptotic NRVMs was assessed by AnnexinV/7AAD labeling. Whereas no differences were apparent at 24 hours, after 72 hours the percentage of early apoptotic NRVMs was dramatically lower in the CDC-CM (Figure 4a ) compared to the NHDF-CM (Figure 4b ) and the control FBSfree BM (Figure 4c and 4d ). This effect was partially but significantly reduced when NRVMs were plated for 72 hours with CDC-CM that had been preincubated with both neutralizing anti-VEGF and HGF antibodies (Figure 4e ). The neutralization of both secreted GFs resulted in an excess 23% early apoptotic NRVMs compared to plain CDC-CM. The neutralizing antibodies were not degraded and were still detectable by WB in the media after 72 hours of culture (Online Figure III) .
Effect of CDC-CM on HUVEC Angiogenic Properties In Vitro
CDC transplantation induces both cardiomyogenesis and angiogenesis. 14 To investigate the effects of CM on blood vessel formation, HUVECs were subjected to an in vitro angiogenesis assay in endothelial cell media (Figure 4f ), FBS-free BM (Figure 4g ) or CM (Figure 4h and 4i) . The ability of HUVECs to form complex tube networks was lost in BM, but in the presence of CDC-CM this ability was almost completely recovered (Figure 4h ). This effect was also dramatically greater than that seen with NHDF-CM 
CDCs Release GFs In Vivo
We took advantage of human-specific sequences and epitopes (Online Figure IV) to detect factors secreted by human cells transplanted into injured mouse hearts. SCID mice were subjected to LAD ligation and injected with 10 5 CDCs or NHDFs. One day and 1 week after cell delivery, VEGF, HGF, and IGF1 human mRNAs were detectable in the infarct area of CDC-and NHDF-injected mice (Figure 5a ). Despite that, we could detect human GFs by WB with human-specific antibodies only in CDC-injected animals, although hGAPDH was evident in the infarct and BZ of both CDC-and NHDF-injected animals (Figure 5b ), indicating survival of the cells for three weeks in CDC-injected and for at least 1 week in NHDF-injected hearts.
GFs were also detectable in remote areas, like the right ventricle and septum, 1 day after cell delivery. After 3 weeks bands for hHGF and hIGF1 were faint, but detectable, although hVEGF could no longer be found; nevertheless, CDCs had engrafted and survived in the infarct and border zones, as evidenced by the detection of hGAPDH in tissue lysates by WB (Figure 5b ) and by immunodetection of human cells in tissue sections (data not shown; also previously 14 ) .
The absence in the WB of a hGAPDH band in the BZ after 24 hours can be attributed, at least in part, to the difficulty in distinguishing the infarct from the peri-infarct zone at such an early time point.
CDC-Injected Heart Tissue Displays Higher Tissue Viability and Capillary Density
The 1 week time point was chosen as an optimal time to examine tissue viability and capillary density. One week after cell delivery, GF levels remain high in the heart ( Figure 5 ), and a strong trend toward a higher LVEF is already noticeable in the CDC group compared to the NHDF control (Figure 6a ). Lysates from CDC-injected mice contained higher levels of Akt protein compared to NHDF-injected animals, as shown by WB and relative densitometric analysis (Figure 7a ). Moreover, active Csp3 expression was reduced in CDC-injected hearts relative to controls. These results correlate with a reduced apoptotic rate (Figure 7b ) and higher capillary density in the border zone of CDC-injected mice (Figure 7c ), compared to controls, as assessed by TUNEL and isolectin B4 staining, respectively. Taken together, these data indicate that CDCs suppress postischemic apoptosis and improve blood supply.
Engraftment Levels and Paracrine Contribution
To begin to assess the relative roles of direct differentiation versus paracrine effects, we measured bioluminescence in mice that had been injected with luciferase-labeled CDCs. This method of detecting residual engraftment over time, although limited by factors such as signal attenuation by chest wall tissue and possible gene silencing, offers at least a qualitative sense of transplanted cell survival. Figure 6b shows that, after 1 week, the luciferase signal has already dropped to approximately 30% of that on day 1, and by week 3, cells are no longer detectable using this technique. Similarly low survival at 3 weeks has been previously reported with injected CDCs. 32, 33 Despite this, the overall functional improvement in the CDC-treated group persists 3 weeks post-MI (Figure 6a ), confirming previous findings. 14 Taken at face value, the bioluminescence data suggest that surviving CDCs are entirely irrelevant; however, the method is nonquantitative, because it is susceptible to tissue attenuation and reporter gene silencing. 34 As a means of quantifying how much of the improvement is attributable to direct regeneration versus indirect humoral effects, we calculated the relative contribution of human CDCs to the capillary density in the tissue areas where CDCs were detectable after 1 week. Despite an overall doubling of capillary density in CDC-injected mice, only 9.6Ϯ2.7% of the total capillaries were found to be of human origin (Figure 8a ). This amounts to Ϸ20% of the enhanced angiogenesis; thus, the angiogenic effect reflects both direct differentiation and paracrine effects, but the latter predominates. We next examined the cardiomyogenic effect of CDC transplantation. Consistent with our previous results at 3 weeks, 14 at 1 week the infarct area of Figure V) , as assessed by Masson's trichrome staining. Within those viable areas, 11.8Ϯ4.5% of the myosin heavy chain (MHC)-expressing cells were of human origin (Figure 8b ). This number, although significant, explains only half of the Ϸ20% increase in relative tissue viability revealed by Masson's trichrome staining, and only Ϸ25% of the overall doubling in MHC ϩ nuclei (Figure 8b ). Thus, both direct regeneration and paracrine effects underlie the cardiomyogenic effects of CDC transplantation. No human capillaries or MHCpositive cells were detectable in the NHDF-injected hearts.
CDC-injected mice contained a higher percentage of viable myocardium (Online
If transplanted CDCs were acting to recruit endogenous repair, one might expect to observe an enrichment of endogenous progenitor cells in the vicinity of surviving CDCs. We have thus looked for colocalization of human CDCs with endogenous c-kit ϩ or nkx2.5 ϩ cells. Foci of nonhuman c-kit ϩ cells surrounding injected CDCs are clearly detectable 2 days after cell delivery, with some persistence 1 week (Online Figure VI, a) . Likewise, nkx2.5 ϩ cells accumulate in the infarct area of CDC-injected mice at 1 week after cell delivery, with the proportion of nkx2.5 ϩ nuclei being significantly higher than in NHDF-injected controls (Online Figure VI, b) . These data are consistent with the idea that transplantation of human CDCs recruits endogenous regeneration as part of the salutary mechanism.
Discussion
Because the administration of human CDCs improves cardiac function in a SCID mouse MI model, 14 we investigated the release of relevant GFs (VEGF, HGF, and IGF1) by human CSps and CDCs, and the potential contribution of paracrine mechanisms to the beneficial and protective effects of CDC-CM in vitro and of CDC therapy in vivo.
Preliminary screening of human CSp-and CDC-CM revealed that these populations are capable of releasing many different cytokines and growth factors, and provides leading information for future experiments (Figure 2) . In the present study, though, we selected VEGF, HGF, and IGF1 as our main candidates for more extensive functional studies.
CSps spontaneously release significant and higher amounts of VEGF, HGF, and IGF1 in vitro than do CDCs, as assessed by ELISA. CDCs secrete only VEGF and HGF, although they maintain the transcription of all their mRNAs (Figure 3) . On the other hand, IICSps were able to secrete VEGF at levels comparable to primary CSps, suggesting that at least for this GF the 3D structure might be a key factor influencing its release, possibly because of internal hypoxic stimulation. 35 These results suggest that: (1) the primary CSp is the stage at which paracrine abilities are maximal in vitro; (2) VEGF release is affected by the 3D structure; and (3) HGF and IGF1 release fades with progressive time in culture.
Interestingly, the absolute GF concentrations measured were approximately between 50 and 2000pg/mL, which correspond to the actual range of their circulating concentrations in physiological up to pathological conditions. 36 -38 Furthermore, the expression of these GF receptors in CSps and CDCs (Online Figure II) suggests a possible autocrine feedback effect.
Although our results demonstrate that CSps are more potent in vitro, as far as VEGF, HGF, and IGF1 secretion is concerned, the expansion of progenitor cells as CDCs has proven to be closer to clinical translation (in the ongoing CADUCEUS trial; see http://clinicaltrials.gov for details), because coronary delivery can be safely performed with CDCs. 39 Therefore we have tested the biological effects of CDC-CM and shown for the first time a direct connection between the presence in the media of an active GF secreted by progenitor cells and a functional benefit in vitro. CDC-CM reduces the percentage of early apoptotic NRVMs in vitro ( Figure 4a through 4e) ; this prosurvival effect is partially attributable to secreted VEGF and HGF in a synergistic way, as shown by the reduction of NRVM viability after preincubation of the CDC-CM with both anti-VEGF and HGF neutralizing antibodies (Figure 4e ). CDC-CM also has proangiogenic effects. In fact CDC-CM recovered almost completely the ability of HUVECs to form complex tube networks, which was lost in the unconditioned BM (Figure 4f through 4k) . Again, VEGF secreted by CDCs plays an important role in the global effect, as demonstrated by the neutralizing antibody experiments, which showed a significant reduction in the enhanced tube formation.
We also tested whether CDCs can release GFs in vivo in the same murine MI model where they have been previously shown to improve LV function 3 weeks after MI, 14 a functional benefit confirmed here (Figure 6a ). When acutely injected intramyocardially in infarcted SCID mice, CDCs release VEGF, HGF, and IGF1, detectable for at least 1 week after cell delivery by RT-PCR and WB with human specific primers and antibodies ( Figure 5 ). Despite the fact that in both cell-treated groups human cells had engrafted, as shown by hGAPDH expression, GFs secreted by transplanted cells were detectable only in CDC-injected animals, ie, in the only group shown to achieve a significant functional improvement. The distribution of human GFs in remote areas (right ventricle, septum) 24 hours after cell injection might be attributable to diffusion via a relatively intact vascular system at that time, which was no longer functional in the more mature infarct scar 1 week after surgery, thus restraining human GFs around the CDC engraftment zone. Alternatively, the early spread into neighboring areas may simply reflect a greater intensity of GF production soon after injection, also resulting from the presence of many more cells.
Cell survival, particularly in an unfavorable environment (such as ischemic cardiac tissue), mostly depends on the ability of the cell to overcome death triggers and secondarily to promote angiogenesis. In this respect, the in vitro antiapoptotic and proangiogenic effects of CDC-CM correlate with the in vivo observation that, 1 week after cell delivery, Akt was upregulated in tissue samples from CDC-injected animals. Contemporaneously, the active form of the apoptotic effector Csp3 was less expressed in CDC-compared to NHDF-injected hearts ( Figure  7a) . Furthermore, the rate of TUNEL-positive cells was significantly reduced in the border zone of CDC-injected mice, which also displayed higher capillary density compared to controls (Figure 7b and 7c) . Overall, our results imply that the injection of CDCs in infarcted SCID mouse hearts favors higher tissue viability in the infarct and peri-infarct areas, and consistently correlates with reduced apoptosis and improved blood supply. This notion is coherent with previous histological data showing a higher percentage of viable myocardium in the infarct area of CDC-injected, as compared to NHDF-injected mice, 14 confirmed at the 1 week time point in the present study (Online Figure V) .
Human CDCs and/or their progeny persist for at least three weeks, as gauged by the robust hGAPDH protein signal, whereas NHDFs disappear sometime between 1 and 3 weeks. It is not yet clear whether the persistence of CDCs reflects their multilineage differentiation, 14 a survival advantage conferred by paracrine effects such as those described here, or a combination of both mechanisms. Accordingly, we also attempted a quantitative evaluation of the balance between direct and indirect beneficial effects in CDC therapy (Figure 8 ). The quantification of human nuclear antigen (HNA)-positive capillaries in the border zone indicates that, after one week, CDCs directly contribute to approximately 10% of the overall capillary density in the areas of CDC engraftment. Even if this fraction is subtracted, there is still a statistically significant difference between the CDC and the NHDF groups, confirming the major role of indirect paracrine induction by CDCs.
To evaluate direct contributions to cardiomyogenesis in the areas of engraftment, we quantified the fraction of HNA/MHC double-positive cells in the viable areas of myocardium in the infarct of CDC-injected mice at 1 week (Figure 8b ). Approximately 12% of the MHC-positive cells were also HNA-positive, and this fraction was necessary to reach statistical significance versus the NHDF group, therefore suggesting at least parity between direct and indirect mechanisms.
It is important to point out that paracrine effects might include two distinct phenomena: the first is humoral stimulation of endogenous regeneration, and the second is preservation of preexisting cells. Although we suspect that both are operative, our results do not enable us to conclusively dissect the relative roles of recruitment versus enhanced tissue survival attributable to the demonstrated antiapoptotic effects of CDCs. Direct injection of HGF and IGF1 into the myocardium has been shown to successfully mobilize endogenous cardiac stem cells 40 ; given that CDC transplantation produces these same GFs, involvement of endogenous stem cells is very likely to contribute to the functional improvement, as also suggested by colocalization of injected CDCs with endogenous c-kit ϩ and nkx2.5 ϩ cells (Online Figure VI) . Given that long-term engraftment of transplanted cells is low and that the final benefit reflects both direct and indirect effects, it seems reasonable to focus on enhancing engraftment and paracrine potency, as prime strategies to boost the overall efficacy of cell therapy.
The potential use of cytokines and GFs as cardiac therapeutic tools has been carefully investigated in the past few years, especially by means of gene therapy. Although interesting results have been obtained in preclinical and early clinical studies on proangiogenic treatments for heart failure and coronary disease, unfortunately these protocols involve risks such as pathological angiogenesis, severe inflammatory reactions and arrhythmias. 41, 42 The possibility of a GF release under biological and physiological control through stem cell therapy might offer an ideal combination of strategies. 43 In this respect, an attractive constellation in therapeutic candidates is the dual ability of cardiac progenitor cells to differentiate directly, but also to secrete beneficial molecules and harness tissue preservation and/or endogenous repair. In vitro and in vivo results on cytoprotective effects on cardiomyocytes and on enhanced neovascularization, similar to the ones presented here, have been reported by mesenchymal stem cells, bone-marrow mononuclear cells and endothelial progenitor cells (see elsewhere 12 for a complete review). This, however, is the first report assessing in detail the role and proportion of paracrine effects mediated by a resident cardiac progenitor population.
In conclusion, CSps and CDCs secrete significant amounts of prosurvival and proangiogenic GFs in vitro, and CDCs are able to secrete VEGF, HGF, and IGF1 in a murine cardiac cell therapy model as well. This appears to be a key mechanism, together with their natural propensity for cardiac differentiation, contributing to their regenerative potential and therapeutic effects in the postinfarction period.
Novelty and Significance
What Is Known?
• Cardiac cell therapy for heart failure represents a major opportunity in regenerative medicine, and multiple stem cell populations are currently being evaluated as therapeutic tools, both in preclinical and clinical models.
• Various lines of evidence indicate that direct differentiation of transplanted cells in cardiac tissue is not the only mechanism underlying the observed beneficial outcomes in animal models and early clinical trials.
• CDCs are a resident progenitor population currently in clinical trials; they are easily harvested from percutaneous endomyocardial biopsies, can directly differentiate into multiple lineages when injected into the heart, and they are effective in mouse and pig models of heart failure therapy.
What New Information Does This Article Contribute?
• Human cardiospheres and CDCs are able to secrete a wide variety of humoral factors, and their conditioned media exerts prosurvival and angiogenic biological effects on cell cultures of cardiomyocytes and endothelial cells.
• In a mouse model of myocardial infarction, human CDCs release growth factors in the tissue, reduce apoptosis, and increase both viability and perfusion in heart tissue.
• The direct contribution of injected CDCs to cardiac tissue represents approximately 20% to 50% of the overall increase in capillary and cardiomyocyte densities and tissue viability; accordingly, indirect effects on tissue preservation and/or recruitment of endogenous regeneration significantly contribute to the therapeutic outcome.
We investigated the mechanisms underlying the functional benefit of transplanted cardiosphere-derived cells (CDCs) in the injured heart. Our results show that CDCs have a wide and potent paracrine potential, exerting antiapoptotic and proangiogenic effects in vitro, while improving tissue viability and function in vivo. Quantification of the relative contributions of direct versus indirect mechanisms revealed a major role for CDC-mediated humoral effects on parenchymal preservation and endogenous repair. Although direct differentiation occurs, it accounts for only 20% to 50% of the overall increases in capillary and cardiomyocyte density. The findings stress the importance of early paracrine effects in the mechanism of benefit, even with endogenous cardiac cells that can unambiguously regenerate the heart directly.
